Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

Reducing supplementary oxygen given to intensive care patients does not deliver any clear and obvious health benefits or harm ...

Dr. Maroouf is a clinical scientist and analog astronaut. From simulating life on Mars at the Mars Desert Research Station to exploring healthcare technologies for astronauts, Dr. Maroouf shares how ...

Photo: Qu Dacheng, Vice Mayor of Chaoyang District, delivers remarks at the Global Investment Cooperation Trends Forum ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today announced plans to initiate a multi-national clinical trial ...

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

Schrödinger, Inc. today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies.

Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ...

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

The University of Oxford has received support from European Medicines Agency's (EMA) for its vaccine targeting the deadly ...

Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the ...

Urological cancers are malignancies that affect the organs of the urinary system and male reproductive system. Of these, bladder ...